{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T04:48:04Z","timestamp":1785818884273,"version":"3.56.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jad.2023.02.067","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T12:19:26Z","timestamp":1676895566000},"page":"72-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorder"],"prefix":"10.1016","volume":"329","author":[{"given":"Qian","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingbing","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangdong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangbiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiufeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhenYu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengfen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifeng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lehua","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaohong","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ce","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunqiang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghua","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junqing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2023.02.067_bb0005","doi-asserted-by":"crossref","first-page":"339","DOI":"10.2147\/JPR.S55682","article-title":"Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy","volume":"7","author":"Allen","year":"2014","journal-title":"J. Pain Res."},{"key":"10.1016\/j.jad.2023.02.067_bb0010","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1097\/01.psy.0000204851.15499.fc","article-title":"Comorbid depression, chronic pain, and disability in primary care","volume":"68","author":"Arnow","year":"2006","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.jad.2023.02.067_bb0015","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1097\/YIC.0b013e32830cebed","article-title":"Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg\/day for major depressive disorder in a placebo-controlled trial","volume":"23","author":"Boyer","year":"2008","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.02.067_bb0020","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0893-133X(01)00298-6","article-title":"Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors","volume":"25","author":"Bymaster","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2023.02.067_bb0025","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2023.02.067_bb0030","doi-asserted-by":"crossref","first-page":"562","DOI":"10.4088\/JCP.13m08978","article-title":"Desvenlafaxine 50 and 100 mg\/d versus placebo for the treatment of major depressive disorder: a phase 4, randomized controlled trial","volume":"76","author":"Clayton","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.02.067_bb0035","author":"Association"},{"key":"10.1016\/j.jad.2023.02.067_bb0040","series-title":"Primary Care Diagnosis And Management of Adults With Depression Guideline","author":"Consortium","year":"2022"},{"key":"10.1016\/j.jad.2023.02.067_bb0045","author":"Evaluation"},{"key":"10.1016\/j.jad.2023.02.067_bb0050","author":"Organization"},{"key":"10.1016\/j.jad.2023.02.067_bb0055","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1124\/jpet.106.103382","article-title":"Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor","volume":"318","author":"Deecher","year":"2006","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jad.2023.02.067_bb0060","series-title":"A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder","first-page":"677","volume":"68","author":"DeMartinis","year":"2007"},{"key":"10.1016\/j.jad.2023.02.067_bb0065","doi-asserted-by":"crossref","first-page":"308","DOI":"10.4088\/JCP.v63n0407","article-title":"Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial","volume":"63","author":"Detke","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.02.067_bb0070","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0022-3956(02)00060-2","article-title":"Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression","volume":"36","author":"Detke","year":"2002","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2023.02.067_bb0075","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.euroneuro.2004.01.002","article-title":"Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial","volume":"14","author":"Detke","year":"2004","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.jad.2023.02.067_bb0080","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/JCP.0b013e31822c0a68","article-title":"Symptomatic and functional improvement in employed depressed patients: a double-blind clinical trial of desvenlafaxine versus placebo","volume":"31","author":"Dunlop","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.02.067_bb0085","article-title":"A review of novel antidepressants: a guide for clinicians","volume":"11","author":"Faquih","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.jad.2023.02.067_bb0090","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s00280-018-3664-y","article-title":"Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy","volume":"82","author":"Farshchian","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.jad.2023.02.067_bb0095","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/ijcp.12641","article-title":"Treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomised trial of duloxetine vs. placebo","volume":"69","author":"Gao","year":"2015","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.jad.2023.02.067_bb0100","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4088\/JCP.v63n0309","article-title":"Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial","volume":"63","author":"Goldstein","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2023.02.067_bb0105","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1176\/appi.psy.45.1.17","article-title":"Effects of duloxetine on painful physical symptoms associated with depression","volume":"45","author":"Goldstein","year":"2004","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jad.2023.02.067_bb0110","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.jcp.0000132448.65972.d9","article-title":"Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine","volume":"24","author":"Goldstein","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.02.067_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1527","article-title":"Duloxetine and pregabalin in neuropathic pain of lung cancer patients","volume":"10","author":"G\u00fcl","year":"2020","journal-title":"Brain Behav."},{"key":"10.1016\/j.jad.2023.02.067_bb0120","first-page":"2767","article-title":"Duloxetine hydrochloride enteric tablets in the treatment of major depressive disorder: a multicenter, randomized, double-blind and active drug parallel controlled trial","volume":"23","author":"Hao","year":"2014","journal-title":"Chin.J.New Drugs"},{"key":"10.1016\/j.jad.2023.02.067_bb0125","first-page":"1905","article-title":"ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International Conference on Harmonisation E9 Expert Working Group","volume":"18","author":"ICH","year":"1999","journal-title":"Stat. Med."},{"key":"10.1016\/j.jad.2023.02.067_bb0130","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/01.pra.0000426323.59698.64","article-title":"Efficacy and safety of desvenlafaxine 25 and 50 mg\/day in a randomized, placebo-controlled study of depressed outpatients","volume":"19","author":"Iwata","year":"2013","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.jad.2023.02.067_bb0135","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/JCP.0000000000000775","article-title":"Speed of improvement in symptoms of depression with desvenlafaxine 50 mg and 100 mg compared with placebo in patients with major depressive disorder","volume":"37","author":"Katzman","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"issue":"351\u20133","key":"10.1016\/j.jad.2023.02.067_bb0140","first-page":"356","article-title":"Side effects of antidepressants: an overview","volume":"73","author":"Khawam","year":"2006","journal-title":"Cleve. Clin. J. Med."},{"key":"10.1016\/j.jad.2023.02.067_bb0145","article-title":"The excess costs of depression: a systematic review and meta-analysis","volume":"29","author":"Konig","year":"2019","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"10.1016\/j.jad.2023.02.067_bb0150","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1017\/S1092852900015236","article-title":"Beyond remission: rationale and design of the Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study","volume":"11","author":"Kornstein","year":"2006","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2023.02.067_bb0155","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1177\/0706743716659061","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: introduction and methods","volume":"61","author":"Lam","year":"2016","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.jad.2023.02.067_bb0160","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1440-1819.2007.01666.x","article-title":"Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil","volume":"61","author":"Lee","year":"2007","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jad.2023.02.067_bb0165","first-page":"3","article-title":"The increasing burden of depression","volume":"7","author":"Lepine","year":"2011","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"10.1016\/j.jad.2023.02.067_bb0170","series-title":"A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder","first-page":"16770","volume":"68","author":"Liebowitz","year":"2007"},{"key":"10.1016\/j.jad.2023.02.067_bb0175","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1185\/03007990802161923","article-title":"Efficacy, safety, and tolerability of desvenlafaxine 50 mg\/day and 100 mg\/day in outpatients with major depressive disorder","volume":"24","author":"Liebowitz","year":"2008","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2023.02.067_bb0180","author":"LILLY"},{"key":"10.1016\/j.jad.2023.02.067_bb0185","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1185\/030079906X167453","article-title":"Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study","volume":"23","author":"Nierenberg","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jad.2023.02.067_bb0190","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/14656566.2021.1900826","article-title":"Desvenlafaxine in the treatment of major depression: an updated overview","volume":"22","author":"Norman","year":"2021","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.jad.2023.02.067_bb0195","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.eurpsy.2006.03.004","article-title":"Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial","volume":"21","author":"Perahia","year":"2006","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.jad.2023.02.067_bb0200","doi-asserted-by":"crossref","first-page":"350","DOI":"10.7326\/M15-2570","article-title":"Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: a clinical practice guideline from the American College of Physicians","volume":"164","author":"Qaseem","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jad.2023.02.067_bb0205","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s11920-019-0997-0","article-title":"Global burden of disease and the impact of mental and addictive disorders","volume":"21","author":"Rehm","year":"2019","journal-title":"Curr. Psychiatry Rep."},{"key":"10.1016\/j.jad.2023.02.067_bb0210","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jagp.2013.01.019","article-title":"Acute and long-term treatment of late-life major depressive disorder: duloxetine versus placebo","volume":"22","author":"Robinson","year":"2014","journal-title":"Am. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.jad.2023.02.067_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.554899","article-title":"A systematic review of efficacy, safety, and tolerability of duloxetine","volume":"11","author":"Rodrigues-Amorim","year":"2020","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jad.2023.02.067_bb0220","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jad.2020.01.149","article-title":"Pharmacological management of depression: japanese expert consensus","volume":"266","author":"Sakurai","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.02.067_bb0225","first-page":"37","article-title":"Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison","volume":"11","author":"Sansone","year":"2014","journal-title":"Innov. Clin. Neurosci."},{"key":"10.1016\/j.jad.2023.02.067_bb0230","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(21)02143-7","article-title":"Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic","volume":"398","author":"Santomauro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2023.02.067_bb0235","series-title":"A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder","first-page":"338","volume":"22","author":"Septien-Velez","year":"2007"},{"key":"10.1016\/j.jad.2023.02.067_bb0240","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJM199910283411801","article-title":"An international study of the relation between somatic symptoms and depression","volume":"341","author":"Simon","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2023.02.067_bb0245","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1017\/S1092852900019726","article-title":"SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants","volume":"10","author":"Stahl","year":"2005","journal-title":"CNS Spectr."},{"issue":"Pt 1","key":"10.1016\/j.jad.2023.02.067_bb0250","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.clinthera.2009.07.006","article-title":"Desvenlafaxine 50 and 100 mg\/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies","volume":"31","author":"Tourian","year":"2009","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jad.2023.02.067_bb0255","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/YIC.0b013e3282f41d7e","article-title":"Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine","volume":"23","author":"Trivedi","year":"2008","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.02.067_bb0260","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0893-133X(00)00220-7","article-title":"Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects","volume":"24","author":"Turcotte","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2023.02.067_bb0265","first-page":"228","article-title":"Treatment of major depressive disorders with generic duloxetine and paroxetine: a multi-centered, double-blind, double-dummy, randomized controlled clinical trial","volume":"27","author":"Wang","year":"2015","journal-title":"Shanghai Arch. Psychiatry"},{"key":"10.1016\/j.jad.2023.02.067_bb0270","author":"Wyeth"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503272300229X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016503272300229X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T03:49:52Z","timestamp":1759031392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016503272300229X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":54,"alternative-id":["S016503272300229X"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2023.02.067","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorder","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2023.02.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}